A significant proportion of children with chronic kidney disease (CKD) have unsuspected chromosomal imbalances, including DNA anomalies that have been linked to neurocognitive disorders, according to a new Columbia University Medical Center (CUMC) study. The findings suggest that routine genetic screening of children with CKD could lead to earlier and more precise diagnoses, as well as to more personalized monitoring, prevention, and treatment. Details of the study were published today in the online issue of the Journal of Clinical investigation.
“With conventional clinical findings, we often cannot determine the exact cause of CKD in children,” said study leader Ali G. Gharavi, MD, professor of medicine and chief of the Division of Nephrology at CUMC. “However, our study shows that using a readily available genetic screening tool called chromosomal microarray analysis, it’s possible in many cases to reach a more precise diagnosis and uncover information that can help define a patient’s risk for other disorders, such as autism or diabetes.”
About 13 percent of Americans are affected by CKD. The disease is particularly serious in children, often leading to complications like high blood pressure, heart disease, neurodevelopmental problems, and behavioral deficits. Roughly half of all cases of CKD in children are caused by birth defects, such as an underdeveloped or missing kidney. CKD can also result from hereditary diseases, infection, toxic exposures, and autoimmune disorders. In many patients, the cause cannot be determined.
Dr. Gharavi, together with lead author Miguel Verbistky, PhD, associate research scientist, and their colleagues, hypothesized that copy number variations (CNVs)—gain or loss of bits of DNA—might provide insights into the cause of CKD in children. The team performed chromosomal microarray analyses of 419 children enrolled in the Chronic Kidney Disease in Children (CKiD) Prospective Cohort Study to determine the prevalence of disease-causing CNVs among various categories of pediatric CKD. The data were compared with genomic data on 21,575 healthy pediatric and adult controls.
The researchers found significant CNVs in 31, or 7.4 percent, of the 419 children with CKD (roughly ten-fold the percentage seen in the controls). The most frequent CNVs were deletions in the HNF1B gene. Loss of HNF1B function is associated with renal cysts and diabetes syndrome, which increases one’s susceptibility to kidney malformations, diabetes, and cognitive disorders, among other conditions. Many of the other CNVs that were uncovered were associated with developmental delays, intellectual disabilities, and seizure disorders.
Of the 31 children with significant CNVs, 28 had genetic diagnoses that differed from the clinical diagnosis or that added information that would have altered the care of the patient, according to the study.
“Because kidney problems can be detected early by blood tests, or even by prenatal imaging studies, this offers the opportunity for screening and detecting genomic imbalances before other complications, such as developmental delay, become clinically apparent,” said Dr. Verbistky.
“Our findings should change clinical practice,” said Dr. Gharavi. “Routine genetic screening of kids with CKD would not only improve diagnosis but also help identify those at risk for complications like diabetes and subclinical seizures, which benefit from early detection and treatment.”
The findings also shed light on why children with CKD tend to perform less well in school than their peers. “The prevailing hypothesis,” said Dr. Gharavi, “is that their poor academic performance is due simply to impaired kidney function and the burden of having a chronic illness. But our data suggest that these kids may be underperforming because of an underlying genetic lesion that affects both kidney and neurologic function. If so, it’s important that we identify these potential problems and intervene as early as possible.”
The paper is titled, “Chromosomal Microarrays for the Diagnosis of Pediatric Chronic Kidney Disease.” The other contributors are: Miguel Verbitsky (CUMC), Simone Sanna-Cherchi (CUMC), David A. Fasel (CUMC), Brynn Levy (CUMC), Krzysztof Kiryluk (CUMC), Matthias Wuttke (University of Freiburg, Freiburg, Germany), Alison G. Abraham (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD), Frederick Kaskel (Albert Einstein College of Medicine, Bronx, NY), Anna Köttgen (University of Freiburg and Johns Hopkins Bloomberg School of Public Health), Bradley A. Warady (Children’s Mercy Hospital, Kansas City, MO), Susan L. Furth (University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, PA), and Craig S. Wong (University of New Mexico Children’s Hospital, Albuquerque, NM).
The authors declare no financial or other conflicts of interest.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.